contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


combigene-appoints-new-chief-scientific-officer

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.

CombiGene

CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Annika Ericsson, current Director Preclinical Development, will take over the role of Chief Scientific Officer, after Karin...

<div class="mfn-body">CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Annika Ericsson, current Director Preclinical Development, will take over the role of Chief Scientific Officer, after Karin Agerman, who has decided to leave the company."Karin has been a highly valued employee and part of the management team since 2018. With her solid experience and thorough understanding of drug development, combined with her sense of business, she has been very successful in driving CombiGene's development forward over the years," says CombiGene's CEO Peter Ekolind. "We will miss Karin, while at the same time we are extremely grateful for the progress she has contributed to through her knowledge and good leadership. We wish her all the best in her new role as Chief Operating Officer at Epigenica," continues Peter.Annika has worked almost as long as Karin in the company and has solid experience in drug development of gene therapies in the preclinical phase and project management. She started by running the preclinical testing of CG01 and has subsequently been project manager in several projects, most recently for CGT2, the lipodystrophy project, and COZY02, CombiGene’s latest gene therapy project that targets severe chronic pain where there is currently a lack of good treatment options."Annika has many years of solid experience in gene therapy development, drug development and project management, combined with a passion for science, which makes her well suited to assume the role of Chief Scientific Officer. I am really looking forward to welcoming her to the management team and our continued collaboration in the company", concludes Peter.</div><div class="mfn-footer mfn-contacts mfn-954154356e40">Contacts<hr>CombiGene AB (publ) Peter Ekolind, CEO Phone: +46 (0)8 35 73 55 peter.ekolind@combigene.com<a rel="noopener" href="https://combigene.com/">www.combigene.com</a> CombiGene AB (publ)&nbsp;Agavägen&nbsp;52A, SE-181&nbsp;55&nbsp;Lidingö, Sweden +46-8-357355 <a rel="noopener" href="mailto:info@combigene.com">info@combigene.com</a></div><div class="mfn-footer mfn-about mfn-2840449e81ce">About CombiGene<hr>CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties. &nbsp; The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.Sign up&nbsp;<a rel="noopener" href="https://combigene.com/ingeneious/">here</a>&nbsp;to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at <a rel="noopener" href="https://combigene.com/">combigene.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/1fbdaee2-e7ec-4809-94bd-cabe66ea3d2e/combigene-appoints-new-chief-scientific-officer.pdf" class="mfn-generated mfn-primary">CombiGene appoints new Chief Scientific Officer</a></div>

Stay up to date with our newsletter